A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT07060989

Patient View

This Phase 1/2a open-label study evaluates NTS071's safety, tolerability, PK, and preliminary efficacy in adults with advanced TP53 Y220C-mutated solid tumors. It includes dose escalation and cohort expansion phases. Eligible participants are ≥18 years, have progressive disease post-treatment, measurable lesions, ECOG PS 0-1, and adequate organ function. NTS071 is administered orally.

Patient Parameters

Program Overview

This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

Description

This is a Phase 1/2a, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary efficacy of NTS071 in subjects with unresectable locally advanced or metastatic solid tumors containing a TP53 Y220C mutation.

This study includes two parts: Phases 1 and 2a. The Phase 1 part consists of the dose escalation and backfill part; The Phase 2a part consists of the cohort expansion part.

Eligibility Criteria

Inclusion Criteria

  1. Male or female subjects, ≥ 18 years
  2. Advanced solid tumors with TP53 Y220C mutation
  3. Previously treated with one or more lines of anticancer therapy and progressive disease
  4. At least one measurable lesion according to RECIST version 1.1 criteria
  5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  6. Adequate organ and bone marrow function

Exclusion Criteria

  1. Known CNS primary tumor and active or untreated CNS metastases
  2. History of another primary malignancy that has been diagnosed or required therapy within the past 2 years
  3. Toxicities of prior therapy have not been resolved to ≤ Grade 1 or to baseline
  4. Significant cardiovascular disease, including congestive heart failure
  5. Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active
  6. Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.